This work cautions that a subset of patients likely will not benefit from the combination of navitoclax with a BRAF inhibitor regimen, though also opens the possibility that BCL2A1 expression or change in expression may be a useful biomarker to study in clinical trials of navitoclax in melanoma and may become a biomarker used to exclude patients from future clinical trials with navitoclax in melanoma. The gene discussed is BRAF; the disease is melanoma.